These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32587263)

  • 1. CRISPR-Cas9 generated Pompe knock-in murine model exhibits early-onset hypertrophic cardiomyopathy and skeletal muscle weakness.
    Huang JY; Kan SH; Sandfeld EK; Dalton ND; Rangel AD; Chan Y; Davis-Turak J; Neumann J; Wang RY
    Sci Rep; 2020 Jun; 10(1):10321. PubMed ID: 32587263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-mediated generation and characterization of a Gaa homozygous c.1935C>A (p.D645E) Pompe disease knock-in mouse model recapitulating human infantile onset-Pompe disease.
    Kan SH; Huang JY; Harb J; Rha A; Dalton ND; Christensen C; Chan Y; Davis-Turak J; Neumann J; Wang RY
    Sci Rep; 2022 Dec; 12(1):21576. PubMed ID: 36517654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand.
    Ngiwsara L; Wattanasirichaigoon D; Tim-Aroon T; Rojnueangnit K; Noojaroen S; Khongkraparn A; Sawangareetrakul P; Ketudat-Cairns JR; Charoenwattanasatien R; Champattanachai V; Kuptanon C; Pangkanon S; Svasti J
    BMC Med Genet; 2019 Sep; 20(1):156. PubMed ID: 31510962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants.
    Chan MY; Jalil JA; Yakob Y; Wahab SAA; Ali EZ; Khalid MKNM; Leong HY; Chew HB; Sivabalakrishnan JB; Ngu LH
    Orphanet J Rare Dis; 2023 Aug; 18(1):231. PubMed ID: 37542277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical and gene mutation analysis of three children with late-onset glycogen storage disease type Ⅱ with hypertrophic cardiomyopathy].
    Luo JH; Qiu WJ; Fang D; Ye J; Han LS; Zhang HW; Yu YG; Liang LL; Gu XF
    Zhonghua Er Ke Za Zhi; 2017 Jun; 55(6):423-427. PubMed ID: 28592009
    [No Abstract]   [Full Text] [Related]  

  • 6. Gene Therapy for Pompe Disease: The Time is now.
    Colella P; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease.
    Wang J; Zhou CJ; Khodabukus A; Tran S; Han SO; Carlson AL; Madden L; Kishnani PS; Koeberl DD; Bursac N
    Commun Biol; 2021 May; 4(1):524. PubMed ID: 33953320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Skeletal Muscle Model of Infantile-onset Pompe Disease with Patient-specific iPS Cells.
    Yoshida T; Awaya T; Jonouchi T; Kimura R; Kimura S; Era T; Heike T; Sakurai H
    Sci Rep; 2017 Oct; 7(1):13473. PubMed ID: 29044175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy.
    Muñoz S; Bertolin J; Jimenez V; Jaén ML; Garcia M; Pujol A; Vilà L; Sacristan V; Barbon E; Ronzitti G; El Andari J; Tulalamba W; Pham QH; Ruberte J; VandenDriessche T; Chuah MK; Grimm D; Mingozzi F; Bosch F
    Mol Metab; 2024 Mar; 81():101899. PubMed ID: 38346589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.
    Herzog A; Hartung R; Reuser AJ; Hermanns P; Runz H; Karabul N; Gökce S; Pohlenz J; Kampmann C; Lampe C; Beck M; Mengel E
    Orphanet J Rare Dis; 2012 Jun; 7():35. PubMed ID: 22676651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme.
    Raben N; Jatkar T; Lee A; Lu N; Dwivedi S; Nagaraju K; Plotz PH
    Mol Ther; 2002 Nov; 6(5):601-8. PubMed ID: 12409258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pompe disease ascertained through The Lantern Project, 2018-2021: Next-generation sequencing and enzymatic testing to overcome obstacles to diagnosis.
    Sniderman King L; Pan Y; Nallamilli BRR; Hegde M; Jagannathan L; Ramachander V; Lucas A; Markind J; Colzani R
    Mol Genet Metab; 2023 May; 139(1):107565. PubMed ID: 37087815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classic infantile-onset Pompe disease with histopathological neurologic findings linked to a novel GAA gene 4 bp deletion: A case study.
    Cerón-Rodríguez M; Castillo-García D; Acosta-Rodríguez-Bueno CP; Aguirre-Hernández J; Murillo-Eliosa JR; Valencia-Mayoral P; Escobar-Sánchez A; Salgado-Loza JL
    Mol Genet Genomic Med; 2022 Jul; 10(7):e1957. PubMed ID: 35532199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease.
    Douillard-Guilloux G; Raben N; Takikita S; Ferry A; Vignaud A; Guillet-Deniau I; Favier M; Thurberg BL; Roach PJ; Caillaud C; Richard E
    Hum Mol Genet; 2010 Feb; 19(4):684-96. PubMed ID: 19959526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Novel Compound Heterozygous Mutations of GAA Gene in Mainland Chinese Patient with Classic Infantile-Onset Pompe Disease.
    Li J; Cui Y; Wang X; Wang Q; Wang H; Yan B
    Int Heart J; 2020 Jan; 61(1):178-182. PubMed ID: 31875618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease.
    Schaaf GJ; van Gestel TJM; In 't Groen SLM; de Jong B; Boomaars B; Tarallo A; Cardone M; Parenti G; van der Ploeg AT; Pijnappel WWMP
    Acta Neuropathol Commun; 2018 Nov; 6(1):119. PubMed ID: 30404653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel GAA mutations in patients with Pompe disease.
    Turaça LT; de Faria DO; Kyosen SO; Teixeira VD; Motta FL; Pessoa JG; Rodrigues E Silva M; de Almeida SS; D'Almeida V; Munoz Rojas MV; Martins AM; Pesquero JB
    Gene; 2015 Apr; 561(1):124-31. PubMed ID: 25681614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.
    Fraites TJ; Schleissing MR; Shanely RA; Walter GA; Cloutier DA; Zolotukhin I; Pauly DF; Raben N; Plotz PH; Powers SK; Kessler PD; Byrne BJ
    Mol Ther; 2002 May; 5(5 Pt 1):571-8. PubMed ID: 11991748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
    Wens SC; Kroos MA; de Vries JM; Hoogeveen-Westerveld M; Wijgerde MG; van Doorn PA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2012 Nov; 107(3):485-9. PubMed ID: 23000108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [GAA gene variants and genotype-phenotype correlations in patients with glycogen storage disease type Ⅱ].
    Huang YL; Sheng HY; Jia XF; Su XY; Zhao XY; Xie T; Tang CF; Liu SC; Li XZ; Zhang W; Mei HF; Zeng CH; Liu L
    Zhonghua Er Ke Za Zhi; 2021 Mar; 59(3):189-194. PubMed ID: 33657692
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.